 Jacquelyn Bainbridge
Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anticonvulsants | 5 | 2020 | 178 | 1.550 |
Why?
| | Parkinson Disease | 10 | 2023 | 345 | 1.190 |
Why?
| | Drug Resistant Epilepsy | 1 | 2020 | 45 | 0.670 |
Why?
| | Multiple Sclerosis | 2 | 2016 | 372 | 0.670 |
Why?
| | Seizures | 4 | 2016 | 337 | 0.660 |
Why?
| | Quality of Life | 3 | 2020 | 2343 | 0.600 |
Why?
| | Education, Pharmacy | 2 | 2017 | 121 | 0.570 |
Why?
| | Pharmacy | 1 | 2017 | 28 | 0.560 |
Why?
| | Neurology | 1 | 2017 | 85 | 0.530 |
Why?
| | Psychotropic Drugs | 1 | 2016 | 54 | 0.520 |
Why?
| | Antiparkinson Agents | 3 | 2017 | 26 | 0.490 |
Why?
| | Disability Evaluation | 1 | 2016 | 271 | 0.460 |
Why?
| | Epilepsy | 4 | 2020 | 278 | 0.460 |
Why?
| | Creatine | 4 | 2017 | 51 | 0.430 |
Why?
| | 4-Aminopyridine | 1 | 2012 | 21 | 0.410 |
Why?
| | Potassium Channel Blockers | 1 | 2012 | 29 | 0.410 |
Why?
| | Immunotherapy | 1 | 2016 | 473 | 0.400 |
Why?
| | Gait Disorders, Neurologic | 1 | 2012 | 41 | 0.390 |
Why?
| | Drug Interactions | 5 | 2016 | 337 | 0.340 |
Why?
| | Gait | 1 | 2012 | 250 | 0.340 |
Why?
| | Piracetam | 1 | 2009 | 15 | 0.330 |
Why?
| | Fructose | 2 | 2008 | 100 | 0.330 |
Why?
| | Restless Legs Syndrome | 3 | 2016 | 20 | 0.320 |
Why?
| | Walking | 1 | 2012 | 422 | 0.310 |
Why?
| | Monoamine Oxidase Inhibitors | 1 | 2008 | 15 | 0.310 |
Why?
| | Monoamine Oxidase | 1 | 2008 | 27 | 0.310 |
Why?
| | Epistaxis | 1 | 2006 | 11 | 0.270 |
Why?
| | Caffeine | 2 | 2017 | 56 | 0.260 |
Why?
| | Diabetic Neuropathies | 1 | 2006 | 78 | 0.250 |
Why?
| | Depression | 3 | 2009 | 1133 | 0.240 |
Why?
| | Patient Compliance | 1 | 2009 | 524 | 0.240 |
Why?
| | Disease Progression | 4 | 2017 | 2371 | 0.200 |
Why?
| | Dronabinol | 2 | 2023 | 118 | 0.200 |
Why?
| | Cannabidiol | 1 | 2023 | 60 | 0.200 |
Why?
| | Pain | 1 | 2006 | 701 | 0.180 |
Why?
| | Humans | 27 | 2023 | 114045 | 0.170 |
Why?
| | Volatilization | 1 | 2019 | 49 | 0.170 |
Why?
| | Dopamine Agonists | 2 | 2016 | 32 | 0.160 |
Why?
| | Nebulizers and Vaporizers | 1 | 2019 | 77 | 0.160 |
Why?
| | Cannabis | 2 | 2023 | 383 | 0.160 |
Why?
| | Ketosis | 1 | 1999 | 12 | 0.160 |
Why?
| | Starvation | 1 | 1999 | 21 | 0.160 |
Why?
| | Comorbidity | 2 | 2016 | 1447 | 0.150 |
Why?
| | Pharmaceutical Services | 1 | 1999 | 76 | 0.150 |
Why?
| | Severity of Illness Index | 5 | 2017 | 2537 | 0.150 |
Why?
| | Air Pollution | 1 | 2019 | 169 | 0.140 |
Why?
| | Schools, Pharmacy | 1 | 2017 | 48 | 0.140 |
Why?
| | Metabolic Diseases | 1 | 2017 | 98 | 0.130 |
Why?
| | Cognition | 1 | 2023 | 990 | 0.130 |
Why?
| | Teratogens | 1 | 2015 | 8 | 0.130 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2015 | 23 | 0.130 |
Why?
| | Female | 16 | 2020 | 59324 | 0.130 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2017 | 180 | 0.120 |
Why?
| | Drug Synergism | 1 | 2016 | 315 | 0.120 |
Why?
| | Pharmacists | 1 | 2017 | 231 | 0.120 |
Why?
| | Psychiatry | 1 | 2017 | 154 | 0.120 |
Why?
| | Monitoring, Physiologic | 1 | 2016 | 248 | 0.110 |
Why?
| | Electrocardiography | 1 | 2017 | 561 | 0.110 |
Why?
| | Lactation | 1 | 2014 | 149 | 0.110 |
Why?
| | Heart Rate | 1 | 2017 | 710 | 0.110 |
Why?
| | Male | 12 | 2020 | 55396 | 0.110 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1117 | 0.110 |
Why?
| | Physical Therapy Modalities | 1 | 2016 | 265 | 0.110 |
Why?
| | Treatment Outcome | 3 | 2017 | 9049 | 0.100 |
Why?
| | Double-Blind Method | 4 | 2023 | 1656 | 0.100 |
Why?
| | Aged, 80 and over | 4 | 2015 | 6306 | 0.100 |
Why?
| | Drug Costs | 1 | 2012 | 92 | 0.100 |
Why?
| | Curriculum | 1 | 2017 | 813 | 0.090 |
Why?
| | Purines | 1 | 2012 | 158 | 0.090 |
Why?
| | Aged | 8 | 2017 | 18969 | 0.090 |
Why?
| | Pregnancy Complications | 1 | 2014 | 430 | 0.090 |
Why?
| | Epilepsies, Partial | 1 | 2009 | 29 | 0.080 |
Why?
| | Pyrazoles | 1 | 2012 | 361 | 0.080 |
Why?
| | Patient Selection | 1 | 2012 | 629 | 0.080 |
Why?
| | Recovery of Function | 1 | 2012 | 573 | 0.080 |
Why?
| | Genetic Predisposition to Disease | 1 | 2017 | 2090 | 0.080 |
Why?
| | Mental Disorders | 1 | 2016 | 889 | 0.080 |
Why?
| | Prognosis | 1 | 2016 | 3315 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1381 | 0.080 |
Why?
| | Middle Aged | 10 | 2017 | 26605 | 0.080 |
Why?
| | Polypharmacy | 1 | 2009 | 74 | 0.070 |
Why?
| | Citalopram | 1 | 2008 | 28 | 0.070 |
Why?
| | Memory Disorders | 1 | 2009 | 153 | 0.070 |
Why?
| | Health Services | 1 | 2008 | 103 | 0.070 |
Why?
| | Neoplasms | 1 | 2020 | 2086 | 0.070 |
Why?
| | Risk Assessment | 1 | 2016 | 2958 | 0.070 |
Why?
| | Accreditation | 1 | 2007 | 76 | 0.070 |
Why?
| | Community Pharmacy Services | 1 | 2007 | 42 | 0.070 |
Why?
| | Longitudinal Studies | 3 | 2017 | 2384 | 0.070 |
Why?
| | Pharmacy Service, Hospital | 1 | 2007 | 83 | 0.070 |
Why?
| | Follow-Up Studies | 2 | 2017 | 4392 | 0.060 |
Why?
| | Kidney Diseases | 1 | 2009 | 349 | 0.060 |
Why?
| | Data Collection | 1 | 2008 | 618 | 0.060 |
Why?
| | Drug Therapy, Combination | 1 | 2008 | 949 | 0.060 |
Why?
| | Physician-Patient Relations | 1 | 2009 | 459 | 0.060 |
Why?
| | Adult | 6 | 2017 | 30375 | 0.060 |
Why?
| | Patient Education as Topic | 1 | 2009 | 666 | 0.060 |
Why?
| | Chronic Disease | 1 | 2009 | 1577 | 0.050 |
Why?
| | Clinical Competence | 1 | 2007 | 882 | 0.040 |
Why?
| | 2-Propanol | 1 | 2019 | 19 | 0.040 |
Why?
| | Limit of Detection | 1 | 2019 | 53 | 0.040 |
Why?
| | Food-Drug Interactions | 1 | 1999 | 6 | 0.040 |
Why?
| | Risk Factors | 1 | 2012 | 8614 | 0.040 |
Why?
| | Calibration | 1 | 2019 | 125 | 0.040 |
Why?
| | Diet, Protein-Restricted | 1 | 1999 | 10 | 0.040 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2019 | 161 | 0.040 |
Why?
| | Surface Properties | 1 | 2019 | 385 | 0.040 |
Why?
| | Dietary Carbohydrates | 1 | 1999 | 138 | 0.040 |
Why?
| | Cannabinoids | 1 | 2019 | 115 | 0.040 |
Why?
| | Catechol O-Methyltransferase Inhibitors | 1 | 1997 | 3 | 0.040 |
Why?
| | Environmental Monitoring | 1 | 2019 | 255 | 0.040 |
Why?
| | Tandem Mass Spectrometry | 1 | 2019 | 410 | 0.040 |
Why?
| | Dietary Fats | 1 | 1999 | 287 | 0.040 |
Why?
| | Autonomic Nervous System | 1 | 2017 | 66 | 0.030 |
Why?
| | Marijuana Smoking | 1 | 2019 | 224 | 0.030 |
Why?
| | Gene-Environment Interaction | 1 | 2017 | 182 | 0.030 |
Why?
| | Women | 1 | 2015 | 51 | 0.030 |
Why?
| | Hemodiafiltration | 1 | 1995 | 9 | 0.030 |
Why?
| | Ciprofloxacin | 1 | 1995 | 23 | 0.030 |
Why?
| | Palliative Care | 1 | 2020 | 641 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 1997 | 743 | 0.030 |
Why?
| | Central Nervous System Stimulants | 1 | 2015 | 140 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2008 | 1836 | 0.030 |
Why?
| | Consensus | 1 | 2016 | 532 | 0.030 |
Why?
| | Pregnancy | 2 | 2015 | 5499 | 0.030 |
Why?
| | Counseling | 1 | 2015 | 342 | 0.030 |
Why?
| | Adenosine A2 Receptor Antagonists | 1 | 2012 | 10 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 2012 | 115 | 0.020 |
Why?
| | Genotype | 1 | 2017 | 1757 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 662 | 0.020 |
Why?
| | Animals | 1 | 2012 | 31565 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2015 | 636 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1331 | 0.020 |
Why?
| | Vasodilator Agents | 1 | 2012 | 302 | 0.020 |
Why?
| | Age Factors | 1 | 2017 | 2885 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2017 | 1880 | 0.020 |
Why?
| | Exercise Test | 1 | 2012 | 547 | 0.020 |
Why?
| | Periodicity | 1 | 2008 | 54 | 0.020 |
Why?
| | Headache | 1 | 2008 | 132 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2008 | 714 | 0.020 |
Why?
| | Recurrence | 1 | 2008 | 925 | 0.020 |
Why?
| | Pilot Projects | 1 | 2008 | 1360 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2008 | 2764 | 0.010 |
Why?
| | Young Adult | 1 | 2015 | 10444 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2015 | 12521 | 0.010 |
Why?
| | Ergolines | 1 | 1997 | 3 | 0.010 |
Why?
| | Catechols | 1 | 1997 | 14 | 0.010 |
Why?
| | Benzophenones | 1 | 1997 | 16 | 0.010 |
Why?
| | Nitrophenols | 1 | 1997 | 32 | 0.010 |
Why?
| | Colorado | 1 | 2007 | 4090 | 0.010 |
Why?
| | Adolescent | 1 | 2015 | 17800 | 0.010 |
Why?
| | Benzothiazoles | 1 | 1997 | 31 | 0.010 |
Why?
| | Thiazoles | 1 | 1997 | 110 | 0.010 |
Why?
| | Receptors, Dopamine D2 | 1 | 1997 | 86 | 0.010 |
Why?
| | Nitriles | 1 | 1997 | 149 | 0.010 |
Why?
| | Indoles | 1 | 1997 | 300 | 0.010 |
Why?
| | Liver Failure | 1 | 1995 | 73 | 0.010 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 1995 | 465 | 0.010 |
Why?
| | Critical Illness | 1 | 1995 | 640 | 0.010 |
Why?
| | Acute Kidney Injury | 1 | 1995 | 637 | 0.000 |
Why?
| | Prospective Studies | 1 | 1995 | 6195 | 0.000 |
Why?
|
|
Bainbridge's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|